ZVRA has 36-month beta value of 1.98. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ZVRA is 54.09M, and currently, short sellers hold a 10.35% ratio of that float. The average trading volume of ZVRA on May 14, 2025 was 472.41K shares.
ZVRA) stock’s latest price update
The stock of Zevra Therapeutics Inc (NASDAQ: ZVRA) has increased by 5.02 when compared to last closing price of 7.87. Despite this, the company has experienced a 10.05% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-05-13 that Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Nichol Ochsner – Vice President Neil McFarlane – President and Chief Executive Officer LaDuane Clifton – Chief Financial Officer Josh Schafer – Chief Commercial Officer Adrian Quartel – Chief Medical Officer Conference Call Participants Sumant Kulkarni – Canaccord Jason Butler – Citizens Eddie Hickman – Guggenheim Lachlan Hanbury – Brown with William Blair Operator Good afternoon and thank you for joining Zevra’s First Quarter 2025 Financial Results and Corporate Update Conference Call. Today’s call is being recorded, and will be available via the Investor Relations section of the company’s website later today.
ZVRA’s Market Performance
Zevra Therapeutics Inc (ZVRA) has seen a 10.05% rise in stock performance for the week, with a 18.41% gain in the past month and a 7.06% surge in the past quarter. The volatility ratio for the week is 5.34%, and the volatility levels for the past 30 days are at 4.84% for ZVRA. The simple moving average for the past 20 days is 10.26% for ZVRA’s stock, with a 4.88% simple moving average for the past 200 days.
Analysts’ Opinion of ZVRA
Many brokerage firms have already submitted their reports for ZVRA stocks, with Cantor Fitzgerald repeating the rating for ZVRA by listing it as a “Overweight.” The predicted price for ZVRA in the upcoming period, according to Cantor Fitzgerald is $25 based on the research report published on January 08, 2025 of the current year 2025.
Guggenheim, on the other hand, stated in their research note that they expect to see ZVRA reach a price target of $20. The rating they have provided for ZVRA stocks is “Buy” according to the report published on October 07th, 2024.
Maxim Group gave a rating of “Buy” to ZVRA, setting the target price at $25 in the report published on September 24th of the previous year.
ZVRA Trading at 8.99% from the 50-Day Moving Average
After a stumble in the market that brought ZVRA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.32% of loss for the given period.
Volatility was left at 4.84%, however, over the last 30 days, the volatility rate increased by 5.34%, as shares surge +14.01% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +7.37% upper at present.
During the last 5 trading sessions, ZVRA rose by +5.66%, which changed the moving average for the period of 200-days by +27.37% in comparison to the 20-day moving average, which settled at $7.48. In addition, Zevra Therapeutics Inc saw -0.90% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZVRA starting from Watton Corey Michael, who purchase 300 shares at the price of $7.84 back on Mar 28 ’25. After this action, Watton Corey Michael now owns 1,800 shares of Zevra Therapeutics Inc, valued at $2,352 using the latest closing price.
Bode John B, the Director of Zevra Therapeutics Inc, purchase 10,000 shares at $7.96 during a trade that took place back on Mar 19 ’25, which means that Bode John B is holding 40,000 shares at $79,624 based on the most recent closing price.
Stock Fundamentals for ZVRA
Current profitability levels for the company are sitting at:
- -3.68 for the present operating margin
- 0.56 for the gross margin
The net margin for Zevra Therapeutics Inc stands at -4.47. The total capital return value is set at -0.6. Equity return is now at value -204.78, with -56.78 for asset returns.
Based on Zevra Therapeutics Inc (ZVRA), the company’s capital structure generated 0.6 points at debt to capital in total, while cash flow to debt ratio is standing at -1.16. The debt to equity ratio resting at 1.52. The interest coverage ratio of the stock is -13.81.
Currently, EBITDA for the company is -76.4 million with net debt to EBITDA at -0.35. When we switch over and look at the enterprise to sales, we see a ratio of 20.07. The receivables turnover for the company is 2.25for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.02.
Conclusion
To put it simply, Zevra Therapeutics Inc (ZVRA) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
